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3-O-sulfotransferase 3 B1Hepatitis B virus infection is a worldwide epidemic and is closely associated with the development of
hepatocellular carcinoma. Nevertheless, the molecular mechanisms of HBV infection and carcinogenesis
remain elusive. Using a hepatocyte model of HBV infection and comparing the gene expression proﬁling
analysis we found that heparan sulfate D-glucosaminyl 3-O-sulfotransferase 3 B1 (HS3ST3B1,3-OST3-B) is
down-regulated in the hepatocytes of chronic HBV infection model. HS3ST3B1 showed potent inhibitory
effect on HBV replication. The inhibitory effect of HS3ST3B1 overexpression was lost upon gene silencing of
HS3ST3B1 or when a catalytic inactive mutant of HS3ST3B1 was expressed. Our study revealed the anti-viral
activity of HS3ST3B1 on HBV replication. It is conceivable that possible therapeutic applications of HBV
infection could be devised by manipulating HS3ST3B1 activity.ted at The Key Laboratory of
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Hepatitis B virus (HBV) is a hepatotropic, non-cytopathic, 3.2 kb
partially double-stranded DNA virus that causes acute and chronic
hepatitis in humans. More than 350 million individuals worldwide are
suffered from chronic HBV infection, which is associated with a high
risk of developing cirrhosis and hepatocellular carcinoma (Seeger and
Mason, 2000). Although the proteins encoded by the HBV genome
have been identiﬁed, the molecular pathway of how chronic HBV
infection causes liver damage and carcinogenesis remain elusive.
The HBV contains a relaxed circular, partially double-stranded
DNA genome of 3.2 kb in length that replicates via an RNA
intermediate (Summers and Mason, 1982). Upon viral entry into
hepatocyte, the viral DNA is ﬁrst converted into a covalently closed
circular DNA known as the cccDNA. The cccDNA is then transcribed by
the cellular RNA polymerase into pregenomic RNA (pgRNA) that isimportant for viral replication, and into subgenomic RNAs that
translate into the viral surface proteins, the core protein, the viral
polymerase, and the regulatory protein named HBx respectively
(Neuveut and Wei, 2010). To complete the viral life cycle, the pgRNA
is ﬁrst packaged into the capsid formed by the core proteins. The
pgRNA will then be converted to the DNA genome within the core
particle by the viral DNA polymerase, which also contains reverse
transcriptase activity. The capsid will then interact with the surface
antigens on the endoplasmic reticulum to form the virion. The mature
virion is then released from the infected cells (Beck and Nassal, 2007).
The control of viral replication is oneof themajor strategies to reduce
the morbidity and mortality associated with chronic HBV infection. At
present, immunomodulatory therapy using IFN-α and direct antiviral
therapy using nucleos(t)ide analogs are the two major strategies for
targeting the life cycle of hepatitis B. However, low efﬁcacy and drug
resistance is themajor problemassociatedwith IFN-α andnucleos(t)ide
analogs therapy respectively (Zoulim and Locarnini, 2009). Therefore,
elucidation of the viral and host factors responsible for HBV infection,
replication and disseminationwill be useful for the future development
of anti-HBV therapeutics.
Heparan sulfate (HS) is ubiquitously expressed on the cell surface
and extracellular matrix of almost all cell types as heparan sulfate
glycosaminoglycans (HSGAGs). HS is implicated in diverse cellular
process including growth control, signal transduction, cell–cell
interaction, and metabolism (Esko and Selleck, 2002; Liu and
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glucuronic acid and N-acetylated glucosamine, followed by a series
of modiﬁcations in the Golgi apparatus including N-deacetylation
and N-sulfation of the acetylglucosamine residues, O-sulfation, and
epimerization of glucuronic to iduronic acid. These secondary
modiﬁcations give rise to enormous structural and functional
diversities (Esko and Lindahl, 2001). Emerging evidence suggested
that HSGAGs can interact with a large number of biological molecule
and act as docking sites for the binding of various viruses including
herpes simplex virus (Shieh et al., 1992; WuDunn and Spear, 1989),
hepatitis C virus (Barth et al., 2003), hepatitis E virus (Kalia et al.,
2009), human immunodeﬁciency virus type 1 (Mondor et al., 1998),
and HBV (Andreas et al., 2007) respectively. For HBV, cellular entry
requires the interaction between the HSGAGs and the pre-S domain
of the large viral envelope protein.
In this studywe analyzed differential gene expression during HBV
replication using a cell model. Our data suggested that heparan
sulfate 3-O-sulfotransferase isoform 3B (HS3ST3B1) is signiﬁcantly
down-regulated in the presence of the replicating HBV genome.
HS3ST3B1 belongs to a family of enzymes known as 3-O-sulfotrans-
ferase (3-OST) and is responsible for transferring sulfuryl group from
3γ-phosphoadenosine 5γ-phosphosulfate to the 3-OH position of
glucosamine units to form 3-O-sulfated heparan sulfate (3-OS HS).
We further showed that ectopic expression of HS3ST3B1 effectively
inhibited HBV replication and viral protein expression. Our data
implicated a role 3-OS HS in HBV replication and have identiﬁed a
novel host factor in the HBV life cycle.
Results
Down-regulation of HS3ST3B1 expression in HepG2.2.15 cells
To analyze how HBV replication alters gene expression in liver cells,
we compared gene expression proﬁles of HepG2.2.15 and HepG2 cell
lines. HepG2.2.15 cell is a HBV stably transfected cell line constitutively
produces HBV transcripts (Sells et al., 1987). Array-based transcriptional
mapping revealed that transcription of the HBV genome altered the
expression of 1305 genes of the host cells, among them the expression of
118 genes were dysregulated by more than 10-fold. Because HBV is aFig. 1. Expression of HS3ST3B1 in different cell lines. (a) mRNA expression level of HS3ST3B
cells, respectively. HS3ST3B1 mRNA expression level in HepG2 cells was set as 1. (b) Wester
blotting analysis of HS3ST3B1 expression in HepG2-HBV1.1 and HepG2 cells.hepatotropic virus, we hypothesized that an alternation in liver-speciﬁc
gene expressionsmaybe essential for optimal viral replication. Therefore,
we focused on heparan sulfate D-glucosaminyl 3-O-sulfotransferase 3B1
(HS3ST3B1), which is a widely expressed gene with the most abundant
expression in the placenta and the liver (Shworak et al., 1999). HS3ST3B1
was down-regulated by ~13 fold in HepG2.2.15 cells (Supplementary
Fig. 1). To determine if HS3S3B1 is speciﬁcally down-regulated by HBV
transcription, we compared the mRNA expression level between
HepG2.2.15 cells and a panel of cell lines of different origins by qRT-PCR
analysis. As shown in Fig. 1a, our data suggested that the expression of
HS3ST3B1 was the highest in cell lines of liver origin, including HepG2,
Huh7, and QGY cells, respectively, and lower expression level was found
inHeLa cells andHUVEC, respectively. HS3ST3B1 transcriptswere down-
regulated by 10-fold in HepG2.2.15 compared to HepG2 cells. Concor-
dantly, the expression of HS3ST3B1 was also reduced in HepG2.2.15
compared to HepG2 cells as determined by Western blot analysis
(Fig. 1b). To substantiate the association between HBV transcription and
HS3ST3B1 down-regulation, we determined if the expression of
HS3ST3B1was also reduced in HepG2-pHBV1.1, another HBV expressing
HepG2 cell line that was generated by stable expression of a vector
containing 1.1-fold-overlength HBV genome driven by a CMV promoter
(pHBV1.1). Similarly, HS3ST3B1 expression was signiﬁcantly reduced in
HepG2-pHBV1.1 cells compared with HepG2 cells (Fig. 1c). Taken
together, these data suggested that transcription of HBV genome reduces
the expression of HS3S3TB1, which might play a role in the viral
replication process.
HS3ST3B1 inhibits HBV replication and HBV protein expression
To elucidate the role ofHS3ST3B1 inHBV replication,we cotransfected
plasmids expressing ﬂag-tagged HS3ST3B1 (HS3ST3B1-FLAG) with
pHBV1.1, pGEM-HBV1.3 (an expression vector containing a 1.3-fold-
overlength HBV genome driven by the endogenous viral promoter) or
pcDNA3.1 into HepG2 cells. Five days after transfection, cytoplasmic HBV
core DNA was extracted, and viral DNA replication was measured by
Southern blot hybridization. As shown in Fig. 2a, ectopic over-expression
of HS3ST3B1 signiﬁcantly reduced the level of HBV DNA encoded by
pHBV1.1 and pGEM-HBV1.3 respectively. Similarly, HS3ST3B1 inhibits
HBV replication in HepG2-HBV1.1 (supplementary Fig. 2). Because the1 was analyzed by quantitative real-time PCR in HepG2, Huh7, QGY, HeLa and HUVEC
n blotting analysis of HS3ST3B1 expression in HepG2.2.15 and HepG2 cells. (c) Western
Fig. 2. The role of HS3ST3B1 in HBV replication. (a) pHBV1.1 or pHBV1.3 was co-transfected with HS3ST3B1 or pCDNA3.1, respectively. HBV intermediate were extracted from
nucleocapsid and subjected to Southern blot analysis. M, DNA ladder. (b) pHBV1.1 was co-transfected with HS3ST3B1-FLAG, pCDNA3.1, sh-HS3ST3B1, or FLAG-E184Q/H186F,
respectively. At 120 h post-transfection, HBV intermediate were extracted from nucleocapsid and subjected to Southern blot analysis. All experiments were independently repeated
for three times, and representative experiment as shown. M, DNA ladder. (c) The effect of HS3ST3B1 on HBV protein expression. Left, pHBV1.1 was co-transfected with HS3ST3B1-
FLAG, pCDNA3.1, sh-HS3ST3B1, or FLAG-E184Q/H186F, respectively. HBV surface antigen (HBsAg) in the supernatant was analyzed by ELISA assay. HBsAg was measured at every 24
h from 48 h to 120 h post-transfection of pHBV1.1, and the relative HbsAg secretion compared to the pCDNA3.1 transfected group, which was set as 1, was calculated at different time
point. Right, detection of HBV core protein byWestern blot. pHBV1.1 was co-transfected with HS3ST3B1-FLAG, pCDNA3.1, sh-HS3ST3B1, or FLAG-E184Q/H186F, respectively. X hour
after transfection, cells were harvested and subjected to Western blot analysis. All experiments were done in triplicate. Representative results are shown.
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promoter but the level ofHBVDNAwas similarly reduced byHS3ST3B1, it
is likely that HS3ST3B1 exerts its effect on viral replication downstreamof
pgRNA transcription. To assess the effect of HS3ST3B1 depletion
or inactivation on viral replication, pHBV1.1 were co-transfected with
HS3ST3B1-FLAGand vector expressingHS3ST3B1 shRNA (sh-HS3ST3B1),
HS3ST3B1-FLAG mutant (FLAG-E184Q/H186F) (Moon et al., 2004), or
pCDNA3.1 into HepG2 cells. As shown in Fig. 2b, the expression of sh-
HS3ST3B1 abolished the inhibitory effect of HS3ST3B1-FLAG on viral
replication. Similarly, point mutant of HS3ST3B1 that is devoid of
sulfotransferase activity lost its inhibitory function on HBV replication.
Over-expression of these vectors did not alter cell viability over a time
course of ﬁve days (data not shown), suggesting that the effect of
HS3ST3B1 on viral replication was speciﬁc. We next determined if
HS3ST3B1 overexpression affects HBV protein expression. Similar to its
effect onHBVreplication, overexpressionofHS3ST3B1-FLAG inhibited the
expression of both HBV surface protein (HBsAg) and core protein (HBc),
whereas the inhibition was abolished by shRNA-mediated silencing of
ectopic HS3ST3B1 or overexpression of FLAG-E184Q/H186F (Fig. 2c).
Because core protein is obligatory for nucleocapsid formation that is
important for reverse transcription of pgRNA into RC DNA (Ganem and
Schneider, 2001;Hirschet al., 1990), ourﬁnding suggested thatHS3ST3B1
may inhibit HBV replication via limiting HBc production.
Since 3-O-sulfation is the last step in HS modiﬁcation mediated by
the 3-OST family (Liu and Thorp, 2002), we next determined ifHS3ST3B1 inhibits HBV replication via altering the sulfation of HS. To
this end, the effect of sodium chlorate, an inhibitor of ATP-sulfurylase
(Baeuerle and Huttner, 1986). on HPV replication was examined. Cells
co-transfected with HS3ST3B1-FLAG and HBV1.1 inhibits HBV
replication as expected, but the addition of sodium chlorate did not
reverse the inhibitory effect of HS3ST3B1-FLAG on HBV replication
(Fig. 3), and sodium chlorate also shows toxic effect on HepG2 cells
transfected with pHBV1.1, which result in lower HBV replication level
comparing with cells that were not introduced with sodium chlorate.HS3ST3B1 down-regulates total HBV RNAs but has no effect on HBV
promoter activity
Because HS3ST3B1 inhibited both viral replication and the
expression of core and surface proteins, we determined if HS3ST3B1
regulates the total RNA level of HBV. To this end HS3ST3B1 or vector
control was ectopically expressed with pHBV1.1 in HepG2 cells, and
total viral RNA was measured by RT-qPCR using primers targeting the
0.7 kb mRNA of the viral genome. We found that total HBV RNAs was
reduced in HS3ST3B1 overexpressing cells compared with control
(Fig. 4a). We then determined the effect of HS3ST3B1 on activity of
the core, X, Sp1 and Sp2 promoter using reporter gene assay.
Intriguingly, however, we found that overexpression of HS3ST3B1
does not affect the activity of these promoters (Fig. 4b). The result
Fig. 3. Effect of sodium chlorate on HBV replication. Left, HS3ST3B1-FLAG or pCDNA3.1 was transfected into HepG2 cells with pHBV1.1, 24 h after transfection, cells were treated with
or without 50 mM sodium chlorate. After 120 h, HBV intermediate were extracted from nucleocapsid and subjected to Southern blot. M, DNA ladder. Right, quantiﬁcation of HBV
relative replication with or without sodium chlorate. The intensity of bands from left ﬁgure were quantiﬁed and calculated by Quantity One software.
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inactivation of HBV promoters.Fig. 4. HS3ST3B1 down-regulates total HBV RNA. (a) HepG2 cells were transfected with
pHBV1.1 andpCDNA3.1,HS3T3B1-FLAG, or sh-HS3ST3B1 respectively. After 96 h,HBVmRNA
level was analyzed real time quantitative PCR. (b) HS3ST3B1 expression on HBV promoter
activity. Different luciferase reporter vector was co-transfected with HS3ST3B1-FLAG into
HepG2 cells. Luciferase activity was measured at 36 h post-transfection. For each reporter
construct, normalized luciferase activity of HS3ST3B1-FLAG transfected cells was presented
with reference to cells transfected with pCDNA3.1. No statistical difference was found
between cells transfectedHS3ST3B1-FLAG andpCDNA3.1. For each group, three independent
experiments were conducted.Discussion
Viruses, bacteria, and parasites utilize heparan sulfate as attach-
ment receptors for infection, invasion, and colonization (Rostand and
Esko, 1997; Xia et al., 2002). Recently, heparan sulfate has been shown
to play an important role in HBV infection. Using HepaRG cell line,
Schulze et al. reported that HBV infection required the initial
attachment to the carbohydrate side chains of hepatocyte-associated
heparan sulfate proteoglycans (HSPGs) as attachment receptors
(Andreas et al., 2007). They further demonstrated that heparin and
other highly sulfated polyanions bind to positively charged structures
on the surface of virions, resulting in inhibiting cellular binding and
abrogation of infection. Ying et al demonstrated an almost complete
abrogation of HBV-binding to primary human hepatocytes and the
non-susceptible HepG2 cell line in the presence of heparin and
dextran sulfate (Ying et al., 2002). These ﬁndings revealed that
heparan sulfate may play an important role in controlling HBV entry
and life cycle.
It has been reported that 3-O-sulfation of glucosamine is a rare
modiﬁcation that constitutes the last step in the biosynthesis of HS
(Shworak et al., 1997; Shukla et al., 1999). The 3-OST contain 6
isoforms 3-OST-1, -2, -3A, -3B, -5 and -6 (Lindahl et al., 1980; Shworak
et al., 1999). Each isoform may exhibit distinct cell-type speciﬁc
expression patterns and produce a unique 3-OS HS chain with diverse
functions. The isoform 3-OST-1 produces 3-O HS with anti-thrombin
binding sites and no glycoprotein D binding activity, whereas other
isoforms (such as 3-OST-2, -3, -4 and -6) generate forms of 3-O HS
that can act as gD receptors (Xu et al., 2005). Nonetheless, their
individual physiological functions are not well understood.
In our study, we also found high expression level in hepatoma cell.
We showed that HS3ST3B1 effectively inhibited HBV replication and
viral protein expression in vitro. The inhibitory effect was abolished by
expressing the loss-of-function mutant of HS3ST3B1, suggesting that
the observed effect is related to the catalytic activity of the enzyme.
However, we failed to observe any increase in HBV replication nor
viral gene expression after RNAi silencing of endogenous HS3ST3B1
(data not show), probably because HS3ST3B1 was already down-
regulated substantially during HBV replication. Thus, our results
strongly suggest that HS3ST3B1 may exert anti-viral function on HBV
replication.We further found that the apparent reduction of HBV total
RNA by HS3ST3B1 overexpressionwas not correlatedwith a reduction
in HBV promoter activities.The molecular mechanism behind HS3ST3B1-mediated inhibition
of HBV replication remains to be fully understood. Given the
important role of HS3ST3B1 function in HS biosynthesis, one
possibility is that overexpression of HS3ST3B1 changes the sulfation
homeostasis of HS, which suppressed HBV propagation. Although the
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block the effect of HS3ST3B1 on HBV replication, it is not certain
whether the inhibitor also affect other cellular pathways important
for HBV replication. Recent study show that 3-O -sulfate of HS was
related to some liver disease. Tátrai et al. (2010) proposed that a
change of 3-O-sulfated motifs in the hepatocyte plasma membrane-
localized HS, and intensiﬁed expression of several HS-modifying
enzymes in ﬁbrogenic liver diseases and HCC. Relevant to our
observation is the ﬁnding by Lyon et al. (1994) that the arginine
rich domain of HBc interacts with sulfated heparan sulfate proteogly-
cans to mediate core particle attachment to a wide variety of cell
types. In addition, Hideo et al. (2008) found that HS3ST3B1 is
responsible for the synthesis of a new kind of tetrasulfated
disaccharide unit (Di-tetraS), which is highly expressed in liver. The
authors speculated that Di-tetraS may involve in some liver-speciﬁc
functions of heparan sulfate and pathogen invasion. These data
suggest that HS3ST3B1 could affect the composition of heparin sulfate
and exert certain biological functions.
On the other hand, HS3ST3B1 may participate in some other
important cell function, such as signaling pathways. Keisuke et al.
(2004) reported that Hs3st-B is a novel regulator of the Notch
signaling pathway and controls pattern formation in Drosophila. They
further demonstrated that Hs3st-B RNAi affects the number and size
of endosomal/lysosomal compartments, suggesting that 3-O sulfated
HS may play an important role in intracellular trafﬁcking of Notch
protein. It is noteworthy that HS3ST3B1 is highly conserved in species
and the human HS3ST3B may have similar function.
The interactions between host cells and virus are complex. Host
immune system is to clear exogenous pathogens through immune
response and cytokines, while pathogens are to devise ways to escape
host attack and immune surveillance, such as down-regulating host
genes. Using high throughput gene proﬁling strategy, we identiﬁed
critical host genes that effectively suppress HBV replication. In this
study, we have demonstrated that HS3ST3B1 may function as a HBV
suppressor gene. Future studies should be devoted to understanding
how HS3ST3B1 impinges on HBV replication, and to further explore if
HS3ST3B1 could be a anti-HBV therapeutic target.
Materials and methods
Plasmid construction
FLAG-HS3ST3B1 was constructed by in frame insertion of full length
HS3ST3B1 into pcDNA3.1 that contains a Flag-tag at the C-terminus.
FLAG-E184Q/H186F was generated from FLAG-HS3ST3B1 using the
QuikChange Multi Site-Directed Mutagenesis Kit (Stratagene). sh-
HS3ST3B1 was generated by inserting shRNA targeted sequence (5'-
CCTCAAGTTCTACCAGATGTTCAAGAGACATCTGGTAGAACTT-
GAGGTTTTTT-3') of HS3ST3B1 into shRNA expression vector pTZU6+1
at the restriction sites SalI andXbaI. pHBV1.1wasobtained fromProf. Lin
Lan (The Third MilitaryMedical University, China). pGEM-HBV1.3 was
obtained from Dr. Protzer (University of Heidelberg, Heidelberg,
Germany).
Cell culture and transfection
HepG2, Huh7, QGY (human hepatoma cells), HepG2.2.15 (stably
HBV transfected HepG2 cells), HeLa cells and HUVEC (human
umbilical vein endothelial cells) were maintained in Modiﬁed Eagle's
medium (MEM) containing 10% fetal calf serum. Transfection was
carried out using Lipofectamin 2000TM (Invitrogen).
Microarray experiments and data processing
2 mg of total RNA was used to synthesize cDNA and biotin-tagged
cRNA using the MessageAmpTM II aRNA Ampliﬁcation Kit. Theresulting bio-tagged cRNAs were hybridized to Affymetrix human
Genome U133 Plus 2.0 Array. The arrays were washed and stained on
an Affymetrix Fluidics Station 450, followed by scanning using a
GeneChip Scanner 3000. The data were analyzed using GeneChip
Operating software (GCOS 1.4).
Construction of HBV stable cell line
HepG2 cell was transfected with pHBV1.1 and selected with G418
(1200 μg/ml). Isolated cell colonies with integrated HBV genomewere
selected after conﬁrmed by Southern blot and Western blot analysis
respectively.
Southern blot analysis
HBV replicative intermediates were obtained as follow. Cells from
one 35-mm diameter dish were lysed with 0.5 ml of lysis buffer
containing 10 mM Tris-HCl (pH 8.0), 1 mM EDTA, 1% NP-40, and 2%
sucrose at 37 °C for 10 min. Cell debris and nuclei were removed by
centrifugation, and the supernatant was mixed with 130 μl of 35%
polyethylene glycol (PEG) 8000 containing 1.5 M NaCl. After a 1-
h incubation in ice, viral nucleocapsids were pelleted by centrifuga-
tion at 10,000g for 5 min at 4 °C, followed by a 1-h digestion at 37 °C in
400 μl of digestion buffer containing 0.5 mg/ml pronase (Calbiochem),
0.5% sodiumdodecyl sulfate (SDS), 150 mMNaCl, 25 mMTris-HCl (pH
8.0), and 10 mM EDTA. The digestion mixture was extracted twice
with phenol, and DNA was precipitated with ethanol and dissolved in
TE (10 mM Tris–HCl, pH 8.0, 1 mM EDTA) buffer and separated on
0.8% agarose gels. DNA samples were transferred onto nylon
membranes (Roche, Germany). After ultraviolet crosslinking and
prehybridization, the membranes were hybridized with DIG-labeled
HBV-speciﬁc probe generated by random-primed labeling kit (Roche,
Germany). The signal was detected by exposing on an X-ray ﬁlm and
scanned using the VersaDoc Imaging system (Bio-Rad).
Western blot analysis of HBc and HS3ST3B1 expression
To monitor HBc expression, total proteins (30 μg) were separated
using a 15%SDS polyacrylamidegel and transferred onto polyvinylidene
ﬂuoride membranes (Millipore, Massachusetts, USA). The membranes
were incubated with rabbit anti-core antibody (Dako Cytomation,
Glostrup, Denmark) or anti-GAPDH antibody (Jiamay, China). The
immunoblot signals were detected using enhanced chemiluminescence
reagent (Pierce, USA). To detect HS3ST3B1 expression, 30 μg total
proteins from HepG2.2.15, HepG2-HBV1.1 and HepG2 cells were
separated using a 12% SDS polyacrylamide gel and transferred onto
polyvinylidene ﬂuoride membranes. The membrane was incubated
with anti-HS3ST3B1 polyclonal antibody (Santa Cruz ,USA).
Detection of HBsAg
The levels of HBV surface antigen (HBsAg) in culture medium and
cell extracts were assessed using an enzyme-linked immunosorbent
assay (ELISA) following the manufacturer's protocol (Kehua biotec Inc,
Shanghai, China). Each experiment was performed in triplicate and
independently repeated three times.
Quantiﬁcation of HS3ST3B1 and total HBV mRNA by qPCR
RNA was extracted by DNA-free RNA mini extraction Kit (Watson,
Shanghai, China). HS3ST3B1 and total HBV mRNA levels were
evaluated by quantitative real-time PCR (qPCR) Relative quantiﬁca-
tion was performed using SYBER-Green assays for the target genes,
withβ-actin mRNA as endogenous control. Expression values of target
genes were calculated using the 2−△Ct method.
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pGL3-Cp, pGL3-Xp, pGL3-Sp1, pGL3-Sp2 were constructed
through replace SV40 promoter by 4 of HBV inner promoters into
vector pGL3-control. (Promega, USA), 4 different plasmids were
transfected with HS3ST3B1 or pCDNA3.1 vector control, respectively.
Using pRL-CMV as inner control. 36 h post transfection, cells were
collected for luciferase activity by Dual-Luciferase Reporter Assay
System (Promega ,USA).
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